Evidence map›Paper›PMID 41624627›Full record

ArticleAcute medicine & surgery

Evaluating the Efficacy of Hyperbaric Oxygen Therapy for Acute Carbon Monoxide Poisoning: A Systematic Review and Meta-Analysis.

Motoki Fujita, Masaki Todani, Yasuhiko Ajimi, Tomoaki Yatabe, Shoji Yokobori, Manabu Araki, Norio Chihara, Masao Nagayama, Tetsuya Sakamoto, Ryosuke Tsuruta and 1 more

Erratum issuedAbstract readComment
In one paragraph

Article in Acute medicine & surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Motoki FujitaEmergency and Critical Care Medicine Yamaguchi University Graduate School of Medicine Ube Yamaguchi Japan.ORCID https://orcid.org/0000-0002-0981-847X
Masaki TodaniEmergency and Critical Care Medicine Yamaguchi University Graduate School of Medicine Ube Yamaguchi Japan.
Yasuhiko AjimiDepartment of Emergency Medicine Teikyo University School of Medicine Itabashi-Ku Tokyo Japan.
Tomoaki YatabeEmergency Department Nishichita General Hospital Tokai Aichi Japan.
Shoji YokoboriDepartment of Emergency and Critical Care Medicine Nippon Medical School Bunkyo-Ku Tokyo Japan.ORCID https://orcid.org/0000-0002-7409-704X
Manabu ArakiDepartment of Neurology Kawakita General Hospital Tokyo Japan.
Norio ChiharaDivision of Neurology Kobe University Hospital Kobe Japan.
Masao NagayamaDepartment of Neurology International University of Health and Welfare Narita Hospital Narita Chiba Japan.
Tetsuya SakamotoShowa General Hospital Kodaira Tokyo Japan.
Ryosuke TsurutaEmergency and Critical Care Medicine Yamaguchi University Graduate School of Medicine Ube Yamaguchi Japan.
Japan Resuscitation Council (JRC) Neuroresuscitation Task Force and the Guidelines Editorial Committee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: To reassess the efficacy of hyperbaric oxygen (HBO) therapy for acute carbon monoxide (CO) poisoning through a systematic review and meta-analysis, including a subgroup analysis of treatment pressures exceeding 2.5 atm absolute (ATA). Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating HBO therapy for acute CO poisoning. A literature search was performed in MEDLINE, CENTRAL, and Ichushi-Web databases, focusing on RCTs published up to June 2024. Only adult patients (≥ 18 years) were included, and studies were screened following PRISMA guidelines. Data extraction and quality assessment were conducted by two independent reviewers using the Cochrane risk of bias tool and the GRADE approach. Statistical analysis used a random effects model, with outcomes expressed as odds ratios (OR) and 95% confidence intervals (CI). Results: Six studies were included, and no significant benefit of HBO therapy was observed in terms of reducing mortality or improving neurological outcomes. The subgroup analysis of HBO at ≥ 2.5 ATA also showed no significant advantage over control treatments. Moderate to significant heterogeneity was found across included studies, and the quality of evidence was rated as low to very low. Conclusions: The efficacy of HBO therapy, even at ≥ 2.5 ATA, for improving outcomes in acute CO poisoning remains unproven. Despite these findings, HBO therapy may still hold potential benefits that require further exploration. High-quality, multicenter RCTs are necessary to better define its role in the treatment of CO poisoning. Trial Registration: UMIN Clinical Trials Registry: UMIN000054641.

Indexed as

evidence qualitymortalityneuropsychiatric sequelaenormobaric oxygen

Identifiers

PMID41624627
PMCPMC12853008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.